Misghina Weldegiorgis1, Dick de Zeeuw1, Jamie P Dwyer2, Peter Mol1, Hiddo J L Heerspink3. 1. Department of Clinical Pharmacy and Pharmacology and. 2. Division of Nephrology, Vanderbilt Medical Center, Nashville, Tennessee. 3. Department of Clinical Pharmacy and Pharmacology and h.j.lambers.heerspink@umcg.nl.
Abstract
BACKGROUND AND OBJECTIVES: RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Post hoc analysis of two clinical trials, the Irbesartan Diabetic Nephropathy Trial (IDNT) and Reduction of End points in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial, in patients with type 2 diabetes and nephropathy. The time to a predefined eGFR level of 11 ml/min per 1.73 m2 (eGFR11), calculated by within-patient linear regression, was compared with the time to RRT or sustained serum creatinine ≥6 mg/dl. RESULTS: A large difference was observed in the median time to RRT (779 days) compared with eGFR11 (678 days; P=0.01). We also observed a large variation in the difference between the time to RRT and eGFR11. In IDNT, the hazard ratio for the effect of irbesartan on the serum creatinine ≥6.0 mg/dl end point was 0.60 (95% confidence interval, 0.39 to 0.91; P=0.02), whereas it was smaller for the RRT end point (hazard ratio, 0.78; 95% confidence interval, 0.58 to 1.07; P=0.12). CONCLUSIONS: This study shows a difference in the time to RRT and a fixed eGFR threshold, and shows that the effect of an angiotensin receptor blocker on a filtration-based end point versus RRT varies. This implies that evaluating renoprotective effects of drugs with a combined RRT and doubling of serum creatinine end point may result in evaluating other effects beyond renoprotection alone. Future trials should consider registering all parameters that lead to RRT decisions.
BACKGROUND AND OBJECTIVES: RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Post hoc analysis of two clinical trials, the IrbesartanDiabetic Nephropathy Trial (IDNT) and Reduction of End points in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial, in patients with type 2 diabetes and nephropathy. The time to a predefined eGFR level of 11 ml/min per 1.73 m2 (eGFR11), calculated by within-patient linear regression, was compared with the time to RRT or sustained serum creatinine ≥6 mg/dl. RESULTS: A large difference was observed in the median time to RRT (779 days) compared with eGFR11 (678 days; P=0.01). We also observed a large variation in the difference between the time to RRT and eGFR11. In IDNT, the hazard ratio for the effect of irbesartan on the serum creatinine ≥6.0 mg/dl end point was 0.60 (95% confidence interval, 0.39 to 0.91; P=0.02), whereas it was smaller for the RRT end point (hazard ratio, 0.78; 95% confidence interval, 0.58 to 1.07; P=0.12). CONCLUSIONS: This study shows a difference in the time to RRT and a fixed eGFR threshold, and shows that the effect of an angiotensin receptor blocker on a filtration-based end point versus RRT varies. This implies that evaluating renoprotective effects of drugs with a combined RRT and doubling of serum creatinine end point may result in evaluating other effects beyond renoprotection alone. Future trials should consider registering all parameters that lead to RRT decisions.
Authors: Liang Li; Brad C Astor; Julia Lewis; Bo Hu; Lawrence J Appel; Michael S Lipkowitz; Robert D Toto; Xuelei Wang; Jackson T Wright; Tom H Greene Journal: Am J Kidney Dis Date: 2012-01-26 Impact factor: 8.860
Authors: Rachael L Morton; Paul Snelling; Angela C Webster; John Rose; Rosemary Masterson; David W Johnson; Kirsten Howard Journal: CMAJ Date: 2012-02-06 Impact factor: 8.262
Authors: Vianda S Stel; Friedo W Dekker; David Ansell; Hans Augustijn; Francesco G Casino; Frederic Collart; Patrik Finne; George A Ioannidis; Mario Salomone; Jamie P Traynor; Oscar Zurriaga; Enrico Verrina; Kitty J Jager Journal: Nephrol Dial Transplant Date: 2009-06-10 Impact factor: 5.992
Authors: B M Brenner; M E Cooper; D de Zeeuw; J P Grunfeld; W F Keane; K Kurokawa; J B McGill; W E Mitch; H H Parving; G Remuzzi; A B Ribeiro; M D Schluchter; D Snavely; Z Zhang; R Simpson; D Ramjit; S Shahinfar Journal: J Renin Angiotensin Aldosterone Syst Date: 2000-12 Impact factor: 1.636
Authors: Celine Foote; Rachael L Morton; Meg Jardine; Martin Gallagher; Mark Brown; Kirsten Howard; Alan Cass Journal: Nephrol Dial Transplant Date: 2014-07-23 Impact factor: 5.992
Authors: Moniek W M van de Luijtgaarden; Marlies Noordzij; Charles Tomson; Cécile Couchoud; Giovanni Cancarini; David Ansell; Willem-Jan W Bos; Friedo W Dekker; Jose L Gorriz; Christos Iatrou; Liliana Garneata; Christoph Wanner; Svjetlana Cala; Olivera Stojceva-Taneva; Patrik Finne; Vianda S Stel; Wim van Biesen; Kitty J Jager Journal: Am J Kidney Dis Date: 2012-08-23 Impact factor: 8.860